Health Catalyst, Inc. (NASDAQ:HCAT) Shares Bought by Legato Capital Management LLC

Legato Capital Management LLC raised its stake in Health Catalyst, Inc. (NASDAQ:HCAT) by 3.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 87,992 shares of the company’s stock after purchasing an additional 3,171 shares during the quarter. Legato Capital Management LLC owned about 0.14% of Health Catalyst worth $622,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Impax Asset Management Group plc boosted its holdings in shares of Health Catalyst by 16.4% in the 3rd quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock valued at $20,793,000 after purchasing an additional 360,201 shares during the last quarter. Primecap Management Co. CA raised its stake in shares of Health Catalyst by 1.1% in the 3rd quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock valued at $19,572,000 after acquiring an additional 25,000 shares during the period. Nepsis Inc. raised its stake in shares of Health Catalyst by 67.9% in the 3rd quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock valued at $17,131,000 after acquiring an additional 851,448 shares during the period. Geode Capital Management LLC raised its stake in shares of Health Catalyst by 4.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company’s stock valued at $11,749,000 after acquiring an additional 66,896 shares during the period. Finally, State Street Corp raised its stake in shares of Health Catalyst by 2.5% in the 3rd quarter. State Street Corp now owns 1,163,754 shares of the company’s stock valued at $9,473,000 after acquiring an additional 28,251 shares during the period. Institutional investors and hedge funds own 85.00% of the company’s stock.

Insiders Place Their Bets

In other Health Catalyst news, CFO Jason Alger sold 19,599 shares of the firm’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $8.32, for a total transaction of $163,063.68. Following the completion of the transaction, the chief financial officer now directly owns 86,712 shares of the company’s stock, valued at $721,443.84. This trade represents a 18.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Daniel Lesueur sold 5,209 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $7.51, for a total transaction of $39,119.59. Following the transaction, the chief operating officer now directly owns 91,253 shares of the company’s stock, valued at approximately $685,310.03. This represents a 5.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 81,169 shares of company stock valued at $629,068 in the last ninety days. Corporate insiders own 2.50% of the company’s stock.

Health Catalyst Price Performance

Shares of HCAT stock opened at $5.55 on Friday. The firm has a market cap of $337.72 million, a P/E ratio of -4.11 and a beta of 1.34. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. Health Catalyst, Inc. has a 1-year low of $5.32 and a 1-year high of $10.14. The firm has a fifty day moving average of $6.64 and a two-hundred day moving average of $7.37.

Wall Street Analysts Forecast Growth

HCAT has been the topic of a number of research reports. Canaccord Genuity Group cut their target price on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, January 21st. Royal Bank of Canada cut their target price on shares of Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 15th. Stephens raised their target price on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research note on Thursday, November 14th. Piper Sandler cut their target price on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a research note on Tuesday. Finally, Citigroup dropped their price target on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Health Catalyst presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.20.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.